Across
- 1. Endocrine therapy for adjuvant treatment of HR positive, HER-2 negative, node positive, early breast cancer at high risk of recurrence.
- 4. For the treatment of latent TB causing Mycobacterium tuberculosis.
- 7. Recent bio similar for rituximab.
- 8. As an adjuvant only in moderate to severe COVID - 19 patients.
Down
- 2. For the treatment of schizophrenia in adults.
- 3. For the treatment of neurofibromatosis type I in paediatric (> 3 years) and adults.
- 5. Antifibrinolytic agent approved for idiopathic pulonary fibrosis.
- 6. For the treatment of uncomplicated UTI.